Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: pincus who wrote (12865)	5/23/2014 3:01:19 PM
From: Littlebits	Read Replies (1) \| Respond to of 13111

The FDA letter is dated 5/16. Why in the world did the company keep us hanging for 6 hours into a trading day before issuing a pr?

To: pincus who wrote (12865)	5/23/2014 3:08:32 PM
From: boomertree2	Read Replies (2) \| Respond to of 13111

Littlebits, I was searching for the correct words to describe this result, and I believe you succinctly captured it. Let's hope the $2.02 pps built in a material risk of not getting BTD, otherwise when trading resumes this could be a bloodbath. Most other companies applying for BTD don't mention it for this very reason. Provectus highlighted their BTD application in every PR they made over the last 60 days, which created a certain expectation. Unmet expectations will likely lead to panic selling. I am holding for the long term, and the long term just got a lot longer. The decision to apply for BTD and not pursue Phase III trials will certainly be second guessed. We have lost 3-4 years of time and millions of dollars.